Business Context and Reporting Period
This Form 6-K is filed by BiondVax Pharmaceuticals Ltd. (the "Company") for the month of February 2017. The filing announces the closing of an investment agreement previously disclosed on January 3, 2017.
Key Financial Metrics
The filing details a capital raise rather than operational financial performance. Key metrics include:
- Capital Raised: NIS 10,904,749 (approximately US$2.8 million).
- Shares Issued: 33,760,832 ordinary shares (equivalent to approximately 844,000 ADSs).
- Ownership Stake: The issued shares represent 19.99% of the Company's issued and outstanding capital immediately after issuance and 12.08% on a fully diluted basis.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes
The primary material change is the completion of the equity financing transaction with Angels Investments in Hi Tech Ltd., a private Israeli company controlled by Mr. Marius Nacht. Additionally, Mr. Isaac Devash was appointed as a director of the Company, effective February 14, 2017.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The shares issued in this transaction are not registered under the Securities Act of 1933 and may not be offered or sold in the United States unless registered or an exemption is available. The shares carry a legend prohibiting transfer except in accordance with Regulation S or pursuant to registration.
Investor Verification Checklist
- Verify the exact exchange rate used to convert NIS 10,904,749 to US$2.8 million.
- Confirm the fully diluted share count calculation to validate the 12.08% ownership stake.
- Review the terms of the investment agreement regarding any additional obligations or milestones for the Investor.
- Check the Company's updated cap table to reflect the new 19.99% ownership position.
- Confirm the background and qualifications of the newly appointed director, Mr. Isaac Devash.